Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion-positive non-small cell lung cancer phase 2 study.
A highly selective RET inhibitor shows promising activity against brain tumors in lung cancer, pending direct comparison with existing treatments.
A phase 2 study evaluated the CNS-penetrant RET inhibitor soxataltinib in RET fusion-positive non-small cell lung cancer. The 84.8% response rate and observed intracranial activity are clinically promising, but the single-arm design requires comparative confirmation.
What the study was
- Study design
- Single-arm phase 2 clinical trial
- Population
- Patients with RET fusion-positive non-small cell lung cancer
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Why it surfaced
Strong phase 2 response data in a molecularly defined cancer population merit high-priority downstream review despite the absence of a randomized comparator.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.